AAA Robert Lavine – Page 443

Syndexa finds a way to Mitsubishi cash

US-based biopharma company Syndexa Pharmaceuticals secured $8.5m in series B1 funding from backers including MP Healthcare Venture Management (MPH), a venture capital firm which acts as a subsidiary of pharmaceutical concern Mitsubishi Tanabe Pharma Corporation and its parent company, Mitsubishi Chemical Holdings.  Also participating in the B1 round was the founder of electronics hardware maker… Continue reading Syndexa finds a way to Mitsubishi cash

Priobiodrug compounds its funding with another $19m

Germany-based biopharmaceutical company Probiodrug secured €15m ($19.2m) in funding on Wednesday from investors including Biogen Idec New Ventures, a corporate venturing unit belonging to pharmaceutical corporation Biogen Idec, and biotechnology investment company BB Biotech. Also investing in the round were Edmond de Rothschild Investment Partners, which acts as a division of the Edmond de Rothschild… Continue reading Priobiodrug compounds its funding with another $19m

Abbott enters the world of NeuroGenetic

Abbott Biotech Ventures, one of the corporate venturing funds run by pharmaceutical corporation Abbott Laboratories, invested an undisclosed amount in US-based Alzheimer’s disease therapeutics company NeuroGenetic Pharmaceuticals (NGP) on Wednesday. Founded in 2009, NeuroGenetic’s technology is based around a compound, NGP555, that it claims can detect and reduce the brain plaques associated with Alzheimer’s. The… Continue reading Abbott enters the world of NeuroGenetic